×
About 1,851 results

ALLMedicine™ Oligodendroglioma Center

Research & Reviews  899 results

TEMOBIC: Phase II Trial of Neoadjuvant Chemotherapy for Unresectable Anaplastic Gliomas...
https://doi.org/10.1002/onco.13765
The Oncologist; Tabouret E, Fabbro M et. al.

Mar 30th, 2021 - Treatment with temozolomide and BCNU was associated with substantial response and survival rates for patients with unresectable anaplastic glioma, suggesting potential therapeutic alternative for these patients. The optimal treatment for unresecta...

IDH-mutant gliomas with additional class-defining molecular events.
https://doi.org/10.1038/s41379-021-00795-w 10.1093/jnen/nlz082 10.1093/neuonc/noz052 10.1186/s40478-017-0443-7 10.1093/neuonc/nox132 10.1007/s00401-018-1849-4 10.1038/s41586-020-2209-9 10.1007/s00401-020-02127-9 10.1111/bpa.12832 10.1158/2159-8290.CD-12-0095 10.1016/j.cell.2015.12.028 10.1038/nm.4333 10.1158/1078-0432.CCR-19-0032 10.1126/science.1239947 10.1186/s40478-020-00980-z 10.5858/arpa.2016-0527-OA 10.1200/JCO.2014.58.3922 10.1007/s11060-019-03306-9 10.1186/s40478-020-00898-6 10.1016/j.ccr.2012.08.024 10.1093/neuonc/now274 10.1200/JCO.2012.46.0220 10.1093/neuonc/not146 10.1097/NEN.0b013e3181845622 10.1038/sj.bjc.6605179 10.1007/s00401-011-0802-6 10.1007/s11060-014-1398-1 10.1007/s00432-015-2006-2 10.1016/j.cell.2013.09.034 10.1038/ng.2735 10.1038/ng.2734 10.1056/NEJMoa1402121 10.1111/j.1750-3639.2012.00603.x 10.1126/science.1220834 10.1007/s00401-016-1539-z 10.1038/ng.2682 10.3390/ijms21030753 10.1038/nm.3729 10.1093/jnen/nly022 10.1038/nature10833 10.1007/s00401-015-1405-4 10.1038/ng.2950 10.1227/01.neu.0000430768.25844.4d 10.1002/pbc.24891 10.1158/1535-7163.MCT-15-0758 10.1158/2159-8290.CD-16-1237
Modern Pathology : an Official Journal of the United Stat... Ahrendsen JT, Torre M et. al.

Mar 27th, 2021 - The 2016 WHO classifies IDH-mutant gliomas into oligodendroglioma or diffuse astrocytoma based on co-occurring genetic events. Recent literature addresses the concept of stratifying IDH-mutant gliomas based on prognostically significant molecular ...

NEAT1 Is a Novel Oncogenic LncRNA and Correlated with miR-143 in Pediatric Oligodendrog...
https://doi.org/10.1159/000514330
Pediatric Neurosurgery; Ak Aksoy S, Mutlu M et. al.

Mar 21st, 2021 - The noncoding RNAs (ncRNAs) play a role in biological processes of various cancers including gliomas. The majority of these transcripts are uniquely expressed in differentiated tissues or specific glioma types. Pediatric oligodendroglioma (POG) is...

Heterogeneous Pattern of Differentiation With BCAS1/NABC1 Expression in a Case of Oligo...
https://doi.org/10.1093/jnen/nlaa144
Journal of Neuropathology and Experimental Neurology; Ulloa-Navas MJ, Rubio L et. al.

Feb 5th, 2021 - Heterogeneous Pattern of Differentiation With BCAS1/NABC1 Expression in a Case of Oligodendroglioma.|2021|Ulloa-Navas MJ,Rubio L,Teruel-Sanchis A,Peña-Peña J,García-Verdugo JM,|

Comparative evaluation of intracranial oligodendroglioma and astrocytoma of similar gra...
https://doi.org/10.1007/s00234-021-02636-8 10.1016/B978-0-12-802997-8.00001-3 10.1016/S0093-7754(01)90066-1 10.1097/00125480-200107000-00001 10.1016/S0090-3019(03)00167-8 10.1586/14737140.1.3.348 10.1093/jnen/61.1.58 10.1259/bjr.20150857 10.1158/1078-0432.CCR-17-0560 10.1007/s00234-017-1851-x 10.1016/j.ncl.2018.04.005 10.3174/ajnr.A5572 10.2214/AJR.05.1177 10.3174/ajnr.A3384 10.3174/ajnr.A3352 10.1007/s00234-017-1839-6 10.1007/s00234-014-1426-z 10.1007/s00234-017-1942-8 10.1002/jmri.21080 10.3174/ajnr.A3825 10.3174/ajnr.A4484 10.3174/ajnr.A3915 10.1002/jmri.24021 10.1111/jon.12320 10.1371/journal.pone.0215400 10.1007/s11060-017-2506-9 10.1177/0284185117728981 10.3174/ajnr.A5127 10.1016/j.compbiomed.2018.06.009 10.2967/jnumed.117.202267 10.1016/j.compbiomed.2016.03.027 10.2463/mrms.mp.2017-0178 10.3389/fonc.2019.01164 10.3389/fonc.2019.01371 10.1002/jmri.26704 10.1016/j.ejrad.2018.07.018 10.1016/j.mri.2017.08.003 10.1007/s10916-017-0800-x 10.1109/TKDE.2017.2682249 10.1038/s41598-020-67244-7 10.1007/s11060-010-0317-3 10.1007/s00234-018-2148-4 10.1186/s12885-020-06951-w 10.3174/ajnr.A1377
Neuroradiology Gupta M, Gupta A et. al.

Jan 20th, 2021 - This retrospective study was performed on a 3T MRI to determine the unique conventional MR imaging and T1-weighted DCE-MRI features of oligodendroglioma and astrocytoma and investigate the utility of machine learning algorithms in their differenti...

see more →

Guidelines  5 results

Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics
https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-019-0793-5
Romo,C.,et al

Feb 8th, 2019 - We present the case of a 28-year-old man with an IDH1 and TP53 mutant high grade glioma with abnormalities in chromosomes 1 and 19 suggestive of anaplastic oligodendroglioma that rapidly progressed to widespread metastatic disease. Biopsy of a liv...

The role of surgery in the management of patients with diffuse low grade glioma: A syst...
https://doi.org/10.1007/s11060-015-1867-1
Journal of Neuro-oncology; Aghi MK, Nahed BV et. al.

Nov 4th, 2015 - Should patients with imaging suggestive of low grade glioma (LGG) undergo observation versus treatment involving a surgical procedure? These recommendations apply to adults with imaging suggestive of a WHO grade 2 glioma (oligodendroglioma, astroc...

The role of initial chemotherapy for the treatment of adults with diffuse low grade gli...
https://doi.org/10.1007/s11060-015-1931-x
Journal of Neuro-oncology; Ziu M, Kalkanis SN et. al.

Nov 4th, 2015 - Adult patients (older than 18 years of age) with newly diagnosed World Health Organization (WHO) Grade II gliomas (Oligodendroglioma, astrocytoma, mixed oligoastrocytoma). Is there a role for chemotherapy as adjuvant therapy of choice in treatment...

Management of patients with recurrence of diffuse low grade glioma: A systematic review...
https://doi.org/10.1007/s11060-015-1910-2
Journal of Neuro-oncology; Nahed BV, Redjal N et. al.

Nov 4th, 2015 - These recommendations apply to adult patients with recurrent low-grade glioma (LGG) with initial pathologic diagnosis of a WHO grade II infiltrative glioma (oligodendroglioma, astrocytoma, or oligo-astrocytoma). Do pathologic and molecular charac...

Central nervous system cancers.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124889
Journal of the National Comprehensive Cancer Network : JN... Nabors LB, Ammirati M et. al.

Sep 13th, 2013 - Primary and metastatic tumors of the central nervous system are a heterogeneous group of neoplasms with varied outcomes and management strategies. Recently, improved survival observed in 2 randomized clinical trials established combined chemothera...

see more →

Clinicaltrials.gov  931 results

TEMOBIC: Phase II Trial of Neoadjuvant Chemotherapy for Unresectable Anaplastic Gliomas...
https://doi.org/10.1002/onco.13765
The Oncologist; Tabouret E, Fabbro M et. al.

Mar 30th, 2021 - Treatment with temozolomide and BCNU was associated with substantial response and survival rates for patients with unresectable anaplastic glioma, suggesting potential therapeutic alternative for these patients. The optimal treatment for unresecta...

IDH-mutant gliomas with additional class-defining molecular events.
https://doi.org/10.1038/s41379-021-00795-w 10.1093/jnen/nlz082 10.1093/neuonc/noz052 10.1186/s40478-017-0443-7 10.1093/neuonc/nox132 10.1007/s00401-018-1849-4 10.1038/s41586-020-2209-9 10.1007/s00401-020-02127-9 10.1111/bpa.12832 10.1158/2159-8290.CD-12-0095 10.1016/j.cell.2015.12.028 10.1038/nm.4333 10.1158/1078-0432.CCR-19-0032 10.1126/science.1239947 10.1186/s40478-020-00980-z 10.5858/arpa.2016-0527-OA 10.1200/JCO.2014.58.3922 10.1007/s11060-019-03306-9 10.1186/s40478-020-00898-6 10.1016/j.ccr.2012.08.024 10.1093/neuonc/now274 10.1200/JCO.2012.46.0220 10.1093/neuonc/not146 10.1097/NEN.0b013e3181845622 10.1038/sj.bjc.6605179 10.1007/s00401-011-0802-6 10.1007/s11060-014-1398-1 10.1007/s00432-015-2006-2 10.1016/j.cell.2013.09.034 10.1038/ng.2735 10.1038/ng.2734 10.1056/NEJMoa1402121 10.1111/j.1750-3639.2012.00603.x 10.1126/science.1220834 10.1007/s00401-016-1539-z 10.1038/ng.2682 10.3390/ijms21030753 10.1038/nm.3729 10.1093/jnen/nly022 10.1038/nature10833 10.1007/s00401-015-1405-4 10.1038/ng.2950 10.1227/01.neu.0000430768.25844.4d 10.1002/pbc.24891 10.1158/1535-7163.MCT-15-0758 10.1158/2159-8290.CD-16-1237
Modern Pathology : an Official Journal of the United Stat... Ahrendsen JT, Torre M et. al.

Mar 27th, 2021 - The 2016 WHO classifies IDH-mutant gliomas into oligodendroglioma or diffuse astrocytoma based on co-occurring genetic events. Recent literature addresses the concept of stratifying IDH-mutant gliomas based on prognostically significant molecular ...

NEAT1 Is a Novel Oncogenic LncRNA and Correlated with miR-143 in Pediatric Oligodendrog...
https://doi.org/10.1159/000514330
Pediatric Neurosurgery; Ak Aksoy S, Mutlu M et. al.

Mar 21st, 2021 - The noncoding RNAs (ncRNAs) play a role in biological processes of various cancers including gliomas. The majority of these transcripts are uniquely expressed in differentiated tissues or specific glioma types. Pediatric oligodendroglioma (POG) is...

Heterogeneous Pattern of Differentiation With BCAS1/NABC1 Expression in a Case of Oligo...
https://doi.org/10.1093/jnen/nlaa144
Journal of Neuropathology and Experimental Neurology; Ulloa-Navas MJ, Rubio L et. al.

Feb 5th, 2021 - Heterogeneous Pattern of Differentiation With BCAS1/NABC1 Expression in a Case of Oligodendroglioma.|2021|Ulloa-Navas MJ,Rubio L,Teruel-Sanchis A,Peña-Peña J,García-Verdugo JM,|

Comparative evaluation of intracranial oligodendroglioma and astrocytoma of similar gra...
https://doi.org/10.1007/s00234-021-02636-8 10.1016/B978-0-12-802997-8.00001-3 10.1016/S0093-7754(01)90066-1 10.1097/00125480-200107000-00001 10.1016/S0090-3019(03)00167-8 10.1586/14737140.1.3.348 10.1093/jnen/61.1.58 10.1259/bjr.20150857 10.1158/1078-0432.CCR-17-0560 10.1007/s00234-017-1851-x 10.1016/j.ncl.2018.04.005 10.3174/ajnr.A5572 10.2214/AJR.05.1177 10.3174/ajnr.A3384 10.3174/ajnr.A3352 10.1007/s00234-017-1839-6 10.1007/s00234-014-1426-z 10.1007/s00234-017-1942-8 10.1002/jmri.21080 10.3174/ajnr.A3825 10.3174/ajnr.A4484 10.3174/ajnr.A3915 10.1002/jmri.24021 10.1111/jon.12320 10.1371/journal.pone.0215400 10.1007/s11060-017-2506-9 10.1177/0284185117728981 10.3174/ajnr.A5127 10.1016/j.compbiomed.2018.06.009 10.2967/jnumed.117.202267 10.1016/j.compbiomed.2016.03.027 10.2463/mrms.mp.2017-0178 10.3389/fonc.2019.01164 10.3389/fonc.2019.01371 10.1002/jmri.26704 10.1016/j.ejrad.2018.07.018 10.1016/j.mri.2017.08.003 10.1007/s10916-017-0800-x 10.1109/TKDE.2017.2682249 10.1038/s41598-020-67244-7 10.1007/s11060-010-0317-3 10.1007/s00234-018-2148-4 10.1186/s12885-020-06951-w 10.3174/ajnr.A1377
Neuroradiology Gupta M, Gupta A et. al.

Jan 20th, 2021 - This retrospective study was performed on a 3T MRI to determine the unique conventional MR imaging and T1-weighted DCE-MRI features of oligodendroglioma and astrocytoma and investigate the utility of machine learning algorithms in their differenti...

see more →

News  13 results

Demographic Factors of Patients with Oligodendroglioma: A NCDB Analysis
https://www.mdedge.com/fedprac/avaho/article/207811/mixed-topics/demographic-factors-patients-oligodendroglioma-ncdb?channel=53
Ahmed H, Silberstein PT

Sep 9th, 2019 - Background: Oligodendrogliomas represent about 12% of all brain tumors. Our goal was to compare the demographic factors of patients diagnosed with oligodendroglioma from 2004-2014 identified in the National Cancer Database (NCDB).

Widely metastatic IDH1-mutant glioblastoma with oligodendroglial features and atypical molecular findings: a case report and review of current challenges in molecular diagnostics
https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-019-0793-5
Romo,C.,et al

Feb 8th, 2019 - We present the case of a 28-year-old man with an IDH1 and TP53 mutant high grade glioma with abnormalities in chromosomes 1 and 19 suggestive of anaplastic oligodendroglioma that rapidly progressed to widespread metastatic disease. Biopsy of a liv...

Combo Tx Leads to Survival Benefit in Glioma
https://www.medpagetoday.com/hematologyoncology/braincancer/57228

Apr 6th, 2016 - Action Points Younger adults with low-grade glioma lived more than 5 years longer if they received chemoradiation rather than radiotherapy alone. Note that treatment with both radiation and chemotherapy was one of only two favorable prognostic fac...

Adjuvant PCV Chemo Hikes Oligodendroglioma Survival
https://www.mdedge.com/neurology/article/54736/cns/brain-cancer/adjuvant-pcv-chemo-hikes-oligodendroglioma-survival/page/0/1

Jun 3rd, 2012 - In univariate analysis 1p/19q co-deletions, IDH, and MGMT were all independent prognostic factors for survival (P less than. 0001), with only MGMT falling out in multivariate analysis.

Altered Mental Status
https://www.medscape.com/viewarticle/492741_1

Nov 7th, 2004 - Summary 36 year old female with altered mental status. (Enlarge Image) (Enlarge Image) (Enlarge Image) (Enlarge Image) This entity is classically difficult to distinguish from a: Cerebral astrocytoma Oligodendroglioma Meningioma Metastatic lesion ...

see more →

Patient Education  3 results see all →